RESUMEN

La manera de entender el fenómeno mundial del tabaquismo, su crecimiento y su distribución es crucial para poder controlarlo. El tabaquismo no puede reducirse a un fenómeno cerebral bioquímico como recientemente se ha postulado, ni como el resultado de la mercadotecnia. Se requiere tener un enfoque amplio, que tome en cuenta la experiencia y el conocimiento de diversos especialistas tanto de las ciencias médico-biológicas como de las sociales y económicas. Cualquier visión fragmentada será limitante tanto para el entendimiento del fenómeno como para las estrategias de control.

PALABRAS CLAVE

.

REFERENCIAS

1. US Department of Health, Education, and Welfare. Smoking and Health: A Report of the Advisory Committee to the Surgeon General of the Public Health Service. US Department of Health, Education, and Welfare; Public Health Service. PHS Publication No. 1103, 1964.

2. Guindon GE, Boisclair D. Tendencias pasadas, presentes y futuras del consumo de tabaco. Organización Panamericana de la Salud. Documento No. 6. Serie: Aspectos Económicos del Control del Tabaco. Washington D.C. 2004.

3. Wilkings N, Yürekli A, Hu-Te H. Análisis económico de la demanda de Tabaco. Organización Panamericana de la Salud. Banco Mundial. Washington D. C. 2004. p. 126.

4. Borio G. Tobacco Timeline. 2001. http://www.tobacco.org/resources/history/Tobacco_History.html

5. Calvo JR, López A. El Tabaquismo. Universidad de las Palmas de Gran Canaria. 2003. p. 31-52.

6. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J 1954; 4877: 1451-5.

7. Hill AB, Doll R. Lung cancer and tobacco; the BMJ’s questions answered. Br Med J 1956; (4976): 1160-3.

8. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. Br Med J 1956; 12(5001): 1071-81.

9. Ley General de Salud, Estados Unidos Mexicanos, Última Reforma, 18-01-2005, Título Décimo Tercero, Publicidad, Artículo 309 Bis. Fracción II.

10. World Health Organization. The smoking epidemic: “a fire in the global village”. 25th August, Press Release WHO/61. Geneve. 1997.

11. Consejo Nacional contra las Adicciones (CONADIC). Observatorio mexicano en tabaco, alcohol y otras drogas. Secretaría de Salud. México 2003. p. 63.

12. Consejo Nacional contra las Adicciones. Encuesta Nacional de Adicciones 2002. Tabaco, alcohol y otras drogas. Resumen Ejecutivo. Secretaría de Salud. 2003.

13. Peña-Corona GM, Kuri M, Tapia CR. El consumo de tabaco en México y Encuesta Nacional de Adicciones 1988 (Tabaco). Secretaría de Salud. México. 2000.

14. Campuzano RJC, López AF. 2002.

15. Institute for Global Tobacco Control, 1999 Baltimore, MD USA.

16. Guerin MR, Jenkins RA, Tomkins BA. The chemistry of environmental tobacco smoke: composition and measurement. Chelsea, Michigan: Lewis Publishers, Inc; 1992.

17. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. Journal of Toxicology and Environmental Health 1997; 50: 307-364.

18. National Research Council. Environmental Tobacco Smoke: Measuring exposures and assessing health effects. National Academy Press; 1986.

19. US Department of Health and Human Services. The health consequences of involuntary smoking. A Report of the Surgeon General Washington, DC: US Government Printing Office; 1986.

20. Hoffmann D, Brunnemann KD, Prokopczyk B, et al. Tobacco Specific N-nitrosamines and Areca-Derived N-nitrosamines: Chemistry, Biochemistry, Carcinogenicity, and Relevance to Humans. Journal of Toxicology and Environmental Health 1994; 41: 1-52.

21. Benowitz NL. Nicotine addiction. Primary Care 1999; 26: 611-631.

22. Camí J, Farré M. Drug addiction. N Engl J Med 2003; 349: 975-86.

23. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002; 53: 606-617.

24. Sachs DPL. Tobacco dependence: pathophysiology and treatment. In: Pulmonary Rehabilitation: Guidelines For Success. 4th ed. 2000. Editado por Hodgkin JE, Connors GL & Celli BR. Lippincott Williams and Wilkins.

25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition (DSM-IV) 1994.

26. Henningfield JE, Fant RV. Tobacco use as drug addiction: the scientific foundation. Nicotine Tob Res 1999; 1(Suppl 2): S31-S35.

27. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW. Symptoms of tobacco withdrawal: a replication and extension. Arch Gen Psychiatry 1991; 48: 52-59.

28. Flegal KM, Troiano RP, Pamuk ER, et al. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med 1995; 333: 1165.

29. Froom P, Kristal-Boneh E, Melamed S, et al. Smoking cessation and body mass index of occupationally active men: The Israeli CORDIS study. Am J Public Health 1999; 89: 718.

30. Hudmon KS, Marks JL, Pomerleau CS, Bolt DM, Brigham J, et al. A multidimensional model for characterizing tobacco dependence. Nicotine Tob Res 2003; 5: 655-664.

31. Sbkowski SM, Swan GE, McClure JB. Cigarette smoking and nicotine dependence. The Med Clin N Am 2004; 88: 1453-1465.

32. Fagerstrom KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978; 3: 235-241.

33. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence. A revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.

34. Fagerström KO, Heatherton TF, Kozlowski LT. Nicotine addiction a its assessment. Ear Nose Throat J 1990; 69: 763-765.

35. Radzius A, Gallo JJ, Epstein DH, Gorelick DA, Cadet JL, et al. A factor analysis of the Fagerström Test for Nicotine Dependence (FTND). Nicotine Tob Res 2003; 5: 255-60.

36. Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict 1989; 84: 791-799.

37. US Department of Health and Human Services. Reducing the health consequences of smoking. 25 years of progress. A Report of the Surgeon General. Washington, DC: US Government Printing Office; 1989.

38. International Agency for Research on Cancer. Tobacco Smoking, vol. 38 of IARC monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. World Health Organization; 1986.

39. Doll R, Peto R. Cigarette smoking and bronchial cancer: dose and time relationships among regular smokers and lifelong non-smokers. Journal of Epidemiology and Community Health 1978; 32: 303-313.

40. Austin H, Cole P. Cigarette smoking and leukemia. Journal of Chronic Diseases 1986; 39: 417-421.

41. McLaughlin JK, Hrubec Z, Linet MS, et al. Cigarette smoking and leukemia. Journal of National Cancer Institute 1989; 81: 1262-1263.

42. Shopland DR, Eyre HJ, Pechacek TF. Smoking-attributable mortality in 1991. Is lung cancer now the leading cause of death among smokers in the United States? Journal of the National Cancer Institute 1991; 83: 1142-1148.

43. Wu-Williams A, Samet JM. Epidemiology of lung cancer, 1994 Editado por JM Samet. 1994 Series: Lung Biology in Health and Disease. Vol. 74. p. 71-108.

44. Lazcano PEC, Tovar GV, Meneses GF, Rascón PARA, Hernández AM. Trends in lung cancer mortality in Mexico. Arch Med Res 1997; 28: 565-570.

45. Tovar GVJ, Barquera S, López-Antuñano FJ. Tendencias de mortalidad por cánceres atribuibles al tabaco en México. Salud Pública Mex 2002; supl 1: S20-S28.

46. Kuri-Morales P, Alegre-Díaz J, Mata-Miranda MP, Hernández-Ávila M. Mortalidad atribuible al consumo de tabaco en México. Salud Pública Mex 2002; supl 1: S29-S33.

47. US Department of Health and Human Services. The health consequences of smoking. Chronic obstructive lung disease. A Report of the US Surgeon General. Washington, DC: US Government Printing Office; 1984.

48. Fletcher C, Peto R, Tinker C, Speizer FE (Editors). The Natural History of Chronic Bronchitis and Emphysema, 1976. Oxford: Oxford University Press.

49. Fletcher CM, Peto R. The natural history of chronic airflow obstruction. British Medical Journal 1977; 1: 1645-1648.

50. US Department of Health and Human Services. The health benefits of smoking cessation. A Report of the Surgeon General. Washington, DC: US Government Printing Office; 1990.

51. Kamholz SL. Pulmonary and cardiovascular consequences of smoking. Med Clin North Am 2004; 88(6): 1415-1430.

52. US Department of Health and Human Services. Public Health Service. The Health Consequences of Smoking – Cardiovascular Disease. A report of the Surgeon General. Washington, DC: US Government Printing Office; 1983.

53. Benowitz NL. Pharmacology on nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 597-613.

54. Hellertein MK, Benowitz NL, Neese RA, Schwartz JM, Hosh R, et al. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J Clin Invest 1994; 93: 265-72.

55. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of publishe data. BMJ 1989; 298: 784-8.

56. Benowitz NL. The role of nicotine in smoking-related cardiovascular disease. Preventive Medicine 1997; 26: 412-417.

57. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. British Medical Journal 1989; 298: 789-794.

58. Tengs TO, Osgood ND. The link between smoking and impotent: two decades of evidence. Prev Med 2001; 32: 447-452.

59. US OSHA Occupational Safety and Health Administration. Indoor Air Quality. Department of Labor, may 1994.

60. US Department of Health and Human Services. The health consequences of smoking for women. A Report of the Surgeon General. Washington, DC: US Government Printing Office; 1980.

61. Difranza JR, Lew RA. Effect of maternal cigarette smoking on pregnancy complications and sudden infant death syndrome. The Journal of Family Practice 1995; 40(4): 385-94.

62. Difranza J, Lew R. Morbidity and mortality in children associated with the use of tobacco products by other people. Pediatrics 1996; 97(4): 560-8.

63. Bulterys MG, Greenland S, Kraus JF. Chronic fetal hypoxia and sudden infant death syndrome: interaction between maternal smoking and low hematocrit during pregnancy. Pediatrics 1990; 86: 535-40.

64. Chen Y, Li W, Yu S, Qian W, Chang-Ning. Epidemiologic study of children’s health: I: passive smoking and children’s respiratory diseases. International Journal of Epidemiology 1998; 17: 348-55.

65. Strachan DP, Cook DG. Parental smoking and lower respiratory illness in infancy and early childhood. Thorax 1997; 52: 905-14.

66. Ware JH, Dockery DW, Spiro A, Speizer FE, Ferris BG Jr. Passive smoking, and respiratory health of children living in Six Cities. American Review of Respiratory Disease 1984; 129: 366-74.

67. Tager IB, Weiss ST, Rosner B, Speizer FE. Effect of prenatal cigarette smoking on the pulmonary function of children. American Journal of Epidemiology 1979; 110: 15-26.

68. Tager IB, Weiss ST, Munoz A, Rosner B, Speizer FE. Longitudinal study of the effects of maternal smoking on pulmonary function in children. New England Journal of Medicine 1983; 309: 699-703.

69. Strachan DP, Cook DG. Parental smoking and allergic sensitization in children. Thorax 1998; 53: 117-123.

70. Evans D, Levison MJ, Feldman CH, Clark NM, Wasilewski Y, Levin B, Mellins RB. The impact of passive smoking on emergency room visits of urban children with asthma. American Review of Respiratory Disease 1987; 135: 567-72.

71. Cook DG, Strachan DP. Parental smoking and prevalence of respiratory symptoms and asthma in school age children. Thorax 1997; 52: 1081-94.

72. Etzel RA, Pattishall EN, Haley NJ, Fletcher RH, Henderson FW. Passive smoking and middle ear effusion among children in day care. Pediatrics 1992; 90: 228-32.

73. Strachan DP, Cook DG. Parental smoking, middle ear disease and adenotonsillectomy in children. Thorax 1997; 53: 50-6.

74. Wells AJ. Lung cancer from passive smoking at work. American Journal of Public Health 1998; 88(7): 1025-9.

75. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. British Medical Journal 1997; 315: 980-8.

76. Glantz SA, Parmley WW. Passive smoking and heart disease. Mechanisms and risk. JAMA 1995; 273(13): 1047–53.

77. Hughes, JR, Fiester, S, Goldstein, MG, et al. American Psychiatric Association practice guideline for treatment of patient with nicotine dependency. Am J Psychiatry 1996; 153(Suppl): S1.

78. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000; 283: 3244.

79. Sansores RH, Ramírez-Vengas A, Espinosa-Martínez M, Sandoval RA. Tratamientos para dejar de fumar disponibles en México. Salud Pública de México 2002; 44 supl 1: S116-S124.

80. Smoking and health: a physician’s responsibility. A statement of the joint committee on smoking and health. American College of Chest Physicians, American Thoracic Society, Asia Pacific Society of Respirology, Canadian Thoracic Society, European Respiratory Society, International Union Against Tuberculosis and Lung Disease. Eur Respir J 1995; 8: 1808.

81. Silagy C, Steadd LF. Physician advice for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 4 2002. Oxford: Update Software.

82. Ellis A, Abrahams E. Terapia Racional Emotiva (TRE). Ed. Pax. México. 1983.

83. Lancaster T. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2002; (3): CD001292. Review.

84. Stead LF, Lancaster T. Group behavior therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2002; (3): CD001007. Review.

85. Sansores-Martínez RH, Córdoba Ponce MP, Espinosa Martínez M, Herrera-Kiengerher L, Ramírez-Venegas A y cols. Evaluación del programa cognitivo conductual para dejar de fumar del Instituto Nacional de Enfermedades Respiratorias. Rev Inst Nal Enf Resp 1998; 11: 29-35.

86. Shiffman S, West R, Gilbert D. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res 2004; 6(4): 599-614.

87. Stapleton JA, Russell MAH, Feyeraben C, Wiseman SM, Gustavsson G, et al. Dose effects and predictors of outcome in a randomized trial of transderman nicotine patches in general practice. Addiction 1995; 90: 31-42.

88. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. (Cochrane Review). In: The Cochrane Library, Issue 4 2002. Oxford: Update Software.

89. Glover ED, Sachs DPL, Stitzer ML, et al. Smoking cessation in highly dependent smokers with 4 mg nicotine polacrilex. Am J Health Behavior 1996; 20: 319.

90. Henningfield JE. Nicotine medication for smoking cessation N Engl J Med 1995; 333: 1196-1203.

91. Daughton DM, Fortmann SP, Glover ED, et al. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 1999; 28: 113.

92. Working group for the study of transdermal nicotine in patients with coronary artery disease. Nicotine replacement for patients with coronary artery disease. Arch Intern Med 1994; 154: 989-995.

93. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29: 1422-1431.

94. Mahmarian JJ, Moye LA, Nasser GA, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997; 30: 125.

95. Benowitz NL. Nicotine replacement therapy during pregnancy. JAMA 1991; 266: 3174-3177.

96. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268-1271.

97. Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159: 2033.

98. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2003; (2): CD000031.

99. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med 2001; 135: 423.

100. Hurt RD, Sachs DPL, Glover ED, Offord KP, Dale LC, et al. A Comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195.

101. Jorenby DE, Leischow SSJ, Nides MA, Rennard SI, Jonson JAA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691.

102. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation. Arch Intern Med 2004; 164: 1797-1803.

103. US Department of Health and Human Services. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000.